Prostate cancer patients should not be limited to least costly therapy
A men's health group is organizing an online petition to urge Congress to rescind a CMS practice of restricting prostate cancer patients to the least costly drug alternative.
The Centers for Medicare & Medicaid Services should not have decided that prostate cancer patients seeking drug treatments should be given the least costly alternative (LCA). Rather they should be treated according to what the patients' own physician recommends. To protest against CMS' denial of payment for therapies that go beyond LCAs, the Men's Health Policy Center, part of the Men's Health Network (MHN), has set up an
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.
